Biotech merchants are getting mistreated by their payment processors, and it’s not subtle.
CBD, supplements, and Nutra companies have surged from fringe innovators to economic powerhouses. Clinics are leveraging telehealth and telemedicine, supplement brands are redefining wellness, and new medical technologies are hitting the market faster than regulators can keep up with. From 2023 to 2030, the biotech industry is projected to grow from roughly $1.5 trillion to more than $3.5 trillion.
This isn’t a flash-in-the-pan trend. Biotech is foundational to the future of healthcare, wellness, and human performance.
So why are legacy payment processors punishing this growth with high-risk labels, inflated fees, excessive rolling reserves, and the constant threat of frozen accounts hanging over merchants like a guillotine? The answer is complicated, but it doesn’t make the treatment acceptable.
Why Processors Mistreat CBD, Supplement, & Nutra Merchants
Healthcare has always been considered “high risk” in payments. Insurance disputes, regulatory oversight, and strict compliance frameworks make it far more complex to process than retail or SaaS. For processors, supporting healthcare means ongoing legal review, compliance monitoring, and risk management. That requires expertise, infrastructure, and investment.
Many processors simply don’t want to make that investment. Instead of adapting, they lump all biotech companies into a single high-risk bucket, regardless of individual compliance, track record, or operational maturity.
And the scrutiny becomes even harsher for CBD, supplement, and nutraceutical companies.
Higher Fees & Worse Terms for CBD, Nutra, & Supplements
If biotech companies are playing on hard mode, CBD and nutraceutical merchants are playing on expert.
Nutra products exist under a microscope. There are dozens of regulatory bodies overseeing everything from ingredient sourcing to advertising language. The FDA, FTC, NIH, and state-level agencies all enforce their own rules, and violations can escalate fast. One inaccurate claim. One unapproved ingredient. One misleading testimonial.
That’s all it takes for penalties ranging from warnings and fines to product seizures and federal prosecution.
Why CBD Faces Even More Heat
CBD (cannabidiol) adds another layer of complexity. While CBD itself is federally legal under the 2018 Farm Bill, it’s derived from cannabis, which is the same plant family that produces THC. That association alone makes banks and processors nervous. To make matters worse, state laws don’t agree.
Many CBD products contain trace amounts of THC (often under 0.3%), which is federally permitted. But states like Idaho and Kansas still treat any THC presence as illegal. That means a product that’s compliant in one state could trigger criminal exposure in another.
Here’s what’s potentially at stake if THC levels cross the wrong line in the wrong state:
- Drug possession charges
- Thousands of dollars in fines
- Product seizures
- Potential jail time
For small and mid-sized CBD brands, these risks aren’t always obvious. A sourcing issue, lab error, or labeling oversight can spiral into a catastrophe without the merchant realizing they’ve crossed a line.
The Scrutiny Facing Supplements
The more promises you make, the more scrutiny your industry is going to face. Supplement manufacturers have sometimes promised the world, only to deliver products that mislead and effectively scam millions of patients.
It’s not simple or cheap to run a fully-compliant supplement business. Recent figures show that up to 65% of evaluated facilities have been cited for some form of non-compliance.
That means compliance is key, not just to gain more customers, but to avoid hefty citations.
Why Processors Clamp Down on Biotech
From a processor’s perspective, these risks are contagious. If a merchant violates regulations, the processor can be pulled into investigations, fined, or lose banking relationships.
So instead of building smarter underwriting models, many processors respond by:
- Charging higher fees
- Enforcing longer reserves
- Freezing accounts at the first sign of friction
- Terminating merchants without warning
That’s why CBD, nutra, and supplement companies face stricter scrutiny than almost any other biotech vertical. But strict regulation doesn’t mean merchants have to be powerless.
How CBD, Supplements, & Nutra Companies Can Fight Back Against Processors
High-risk doesn’t have to mean high-stress. Biotech merchants who understand and follow the rules can dramatically improve their processing stability, costs, and long-term growth potential.
Maintain Complete Transparency
Sunlight kills risk. Secrecy amplifies it. Processors panic when they feel surprised. Merchants who hide product details, marketing angles, or future expansion plans are far more likely to trigger freezes or terminations.
Biotech companies should proactively disclose:
- Ingredients and sourcing methods
- Lab testing and COAs
- Fulfillment timelines
- Refund and dispute policies
- Advertising channels and claims
Transparency builds trust. And trust buys flexibility when issues arise.
Avoid Unproven Promises
Marketing hype is expensive, especially when regulators are watching. Many biotech merchants get into trouble not because their products are unsafe, but because their claims are too bold. Promising to “cure,” “treat,” or “reverse” medical conditions is a fast track to FDA and FTC enforcement.
Stick to:
- Structure/function claims
- Evidence-backed benefits
- Conservative, compliant language
If a claim can’t be supported by credible research, it doesn’t belong on your site or in your ads.
Prioritize Regulatory Research & Compliance
Compliance isn’t a box to check. It’s a competitive advantage.
Biotech companies that invest in compliance early avoid catastrophic issues later. That means understanding federal and state regulations, staying current on enforcement trends, and working with third-party verification organizations.
One example is LegitScript, which helps certify healthcare and supplement merchants for advertising platforms and payment providers. While not mandatory for all processors, LegitScript certification signals operational maturity and lowers perceived risk. Compliance-forward brands don’t just survive, they scale.
Add Strict Risk Management
Hope is not a risk strategy. Systems are.
Risk management should be baked into daily operations, including:
- Chargeback monitoring and thresholds
- Clear refund workflows
- Fraud detection tools
- Customer support response SLAs
The fewer disputes you generate, the safer your processing profile becomes—and the more negotiating power you gain.
Optimize Business Operations
Operational chaos is a processor’s nightmare. Late shipping, inconsistent fulfillment, and vague policies all increase chargebacks. Tight operations don’t just protect revenue—they protect relationships with banks and processors.
Clean operations = clean processing history.
Find a Specialized Processor
This is the real unlock.
No amount of compliance can fix a processor that doesn’t understand your industry. Legacy processors treat biotech risk as a liability. Specialized processors treat it as a solvable equation.
That’s where the right partner changes everything.
Finding the Right Processor for Your Business
Not every processor is built for every business, and biotech companies feel that mismatch more than most. If your processor has labeled you “high risk” without offering guidance, education, or tailored support, that’s a red flag. You shouldn’t be punished simply for operating in a regulated industry. You should be supported by a partner who understands it.
The uncomfortable truth is that many processors lack the infrastructure, compliance teams, and industry knowledge required to support CBD, supplement, and nutraceutical merchants. Rather than adapt, they shift the burden onto merchants through higher fees and harsher terms.
At Luqra, we take a different approach. We don’t see biotech growth as a threat. We see it as proof of legitimacy.
We’re preparing our systems for CBD, supplements, and nutra payment processing. Why? Because these industries aren’t going away. They’re evolving, scaling, and professionalizing. And they deserve a payment infrastructure that grows with them.
Here’s what that looks like in practice:
- Industry-specific underwriting that evaluates your business based on biotech realities, not generic risk models.
- Reduced or zero account freezes with proactive compliance reviews and transparent communication lower the chances of sudden shutdowns.
- Fair, predictable pricing without surprise fee hikes. No punitive reserves “just in case.” Pricing reflects your actual risk profile.
- Regulatory-aware 24/7 support with teams who understand FDA, FTC, and state-level considerations, helping you navigate compliance instead of guessing.
- Fast-tracked LegitScript certification that saves your time while optimizing your care capabilities.
Biotech companies are shaping the future of healthcare and wellness. They shouldn’t be held back by outdated payment systems and risk-averse processors who refuse to evolve.
Regulation is real. Risk exists. But punishment isn’t the solution.
If your processor treats your growth like a liability, it’s time for a change.
